Conference Coverage

Study shows value of pretransplant assessment of function, endurance


 

REPORTING FROM THE 2018 BMT TANDEM MEETINGS


Study participants were adults aged 18 years and older (median, 58 years) undergoing a first allogeneic HCT at a single center between 2010 and 2016. Most (83%) were older than age 40 years and 58% were men. About half (51%) had acute myeloid leukemia, and 64% overall had a KPS score of 60-70.


Physical therapists assessed physical performance of all patients within 4 weeks pre-HCT; testing included 25 7-inch step-ups on each side, unassisted sit-to-stands from an 18-inch chair in 30 seconds, weight-bearing ability, need for assistance with ambulation, motor strength in four extremities, sensory or coordination impairment, self-reported pain, and time to recovery of heart rate and oxygen saturation to pre-exercise levels.

“The HCT-CI is a validated tool that predicts nonrelapse mortality and overall survival, but comorbidity alone as a single domain is not a surrogate of overall health or reflection on the true biological age of our patients,” Dr. Rehman said, noting that studies have shown that functional impairment is associated with shorter overall survival, and that patient-reported physical functioning is predictive of overall survival. “The assessment of functional impairment becomes more critical given the aging U.S. population and older patients receiving transplant.”

Traditionally, functional status has been assessed via the KPS, which is a subjective measure and lacks precision, and the HCT-CI has not been studied in the context of the novel outcome measures addressed in the current study, she noted.

Pages

Recommended Reading

KD025 shows promise for steroid-dependent cGVHD
MDedge Hematology and Oncology
CAR T before transplant yields durable remission in B-cell malignancies
MDedge Hematology and Oncology
Xenon imaging could detect lung involvement after HSCT
MDedge Hematology and Oncology
Low microbiota diversity linked to poor survival after transplant
MDedge Hematology and Oncology
Ibrutinib preserves immune memory while fighting cGVHD
MDedge Hematology and Oncology
Posttransplant cyclophosphamide helped reduce GVHD rates
MDedge Hematology and Oncology
High engraftment with new umbilical transplant technique
MDedge Hematology and Oncology
Study: Stick with TMP-SMX for posttransplant PJP prophylaxis
MDedge Hematology and Oncology
Coming soon: CAR T-cell approvals in multiple myeloma
MDedge Hematology and Oncology
Reduced intensity conditioning doesn’t protect fertility
MDedge Hematology and Oncology